Key Points Non-GAAP earnings per share (EPS) of $2.25 in Q2 2025 far surpassed the analyst estimate of $0.32 and rose 923% year-over-year compared to Q2 2024 (non-GAAP adjusted diluted EPS per ADS).

Eli Lilly and Company LLY reported second-quarter 2025 adjusted earnings per share (“EPS”) of $6.31, which beat the Zacks ...

Amgen beat Q2 earnings and revenue expectations, raised 2025 guidance, and reported strong product sales growth across key ...

Adma Biologics Inc. ADMA) on Wednesday reported second-quarter net income of $34.2 million. On a per-share basis, the Ramsey, ...

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

Major indices were in the green early on Thursday after Donald Trump's newly announced chip tariffs included broad exemptions.

Major indices delivered solid gains on Wednesday as market participants thumbed over a fresh batch of corporate earnings.

Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying.

Leading the charge this morning is Smith & Nephew PLC (LSE:SN), up over 11% after the knee- and hip-replacement group ...